STLN Stock Forecast & Price Target

Starling Oncology is supported by strong 3Q26 execution, with revenue of $169.8M up 24% year over year and adjusted EBITDA of $3.4M well ahead of expectations, marking a second consecutive quarter of positive EBITDA and signaling improving earnings power. Its growth engine is increasingly shifting toward higher-margin Specialty Pharmacy and capitated contracts, with pharmacy revenue up 44% to $109.3M, capitated revenue up 40% to $28.7M, and total lives under value-based contracts rising to 2.2M, while the live Nexus platform should deepen script capture and operating leverage. Although Florida timing pushed 2026 capitated revenue guidance lower, the company still has a $1B+ pipeline, improving MLR dynamics, and balance-sheet support from the July refinancing and August revolver, making the long-term growth and margin runway look attractive.

Starling Oncology is facing a deteriorating growth outlook after management cut 2026 capitated revenue guidance to about $110M from roughly $150M because the planned Florida expansion with three anchor delegated health plan partners will not proceed immediately, with no new start date provided. Although the Oregon Medicare Advantage contract covering about 40,000 lives went live on October 1 and management still expects capitated revenue to double in 2027, that outlook is now nearer $220M versus about $300M previously, while heavy debt, reimbursement exposure, and capitation forecasting risk could pressure margins and investment capacity. Additional downside comes from labor shortages, competitive pressure, geographic concentration, and the possibility of further contract losses, all of which could impair patient growth and the path to adjusted EBITDA positive targets for FY26.